Overview

A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide

Status:
Completed
Trial end date:
2007-04-23
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to study the safety and tolerability of teduglutide following a once or possibly twice daily subcutaneous injection for eight consecutive days in healthy subjects. A secondary objective was to study the pharmacokinetics of teduglutide following a once or possibly twice daily injection for eight consecutive days in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Shire
Treatments:
Teduglutide